Every field has a short list of papers that everything else builds on. The top Humanin studies are that foundation: the discovery paper, the mechanism papers, the in-vivo confirmations, and the reviews that organized two decades of follow-up work into a coherent picture. This guide summarizes the most influential published studies on Humanin — what each one asked, what it found, and why the field still cites it. All summaries stay in research framing: cell cultures, animal models, and observational data, with no human-use claims.
Research-use-only disclaimer: Humanin is a research compound, not a medicine and not an FDA-approved drug. All products on this site are sold strictly for laboratory research use. This article summarizes published research for educational purposes only: no medical advice, no usage guidance, no promises about human outcomes.
How This List of the Top Humanin Studies Was Chosen
“Top” needs a definition, because citation counts and influence are not the same as proof. The top Humanin studies below were selected for influence: papers that opened a research direction, settled a mechanism, or became the standard citation other papers reach for. The list moves roughly chronologically, because the field’s logic is chronological — discovery first, mechanisms second, breadth third. Where a paper is open access, the summary links straight to it.
Study 1 — The Discovery: Hashimoto et al., PNAS, 2001
Citation: Hashimoto Y. et al., “A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer’s disease genes and Abeta,” Proceedings of the National Academy of Sciences 98(11):6336–6341 (PubMed 11371646).
What it did: The Nishimoto laboratory built a cDNA library from brain tissue and screened it for any gene that could stop neurons from dying under the assault of familial Alzheimer’s disease genes and amyloid-beta. One clone kept rescuing the cells. The team showed the rescue depended on the peptide’s exact amino-acid sequence, that the peptide was secreted into the culture medium, and that it worked against multiple different AD-related insults — but not against unrelated death triggers like Huntington’s or ALS models, suggesting specificity rather than a generic anti-death effect.
Why it is on every top Humanin studies list: It is the founding paper. It named Humanin, established the Alzheimer’s-neuroprotection framing that defined the field’s first decade, and introduced the mitochondrial-DNA origin that later made Humanin the founding mitochondrial-derived peptide. Every subsequent paper cites it.

Study 2 — Detailed Characterization: Hashimoto et al., Journal of Neuroscience, 2001
Citation: Hashimoto Y. et al., “Detailed characterization of neuroprotection by a rescue factor Humanin against various Alzheimer’s disease-relevant insults,” Journal of Neuroscience 21(23):9235–9245.
What it did: Published the same year as the discovery paper, this was the systematic follow-up: which insults does Humanin protect against, which does it not, and what are the boundaries of the effect? It mapped the neuroprotective profile across a panel of Alzheimer’s-relevant challenges, turning a striking single finding into a characterized phenomenon.
Why it matters: Discovery papers announce; characterization papers convince. This study gave the field the dose of rigor — the boundaries and specificities — that let other labs build on the finding instead of merely admiring it. In top Humanin studies terms, it is the paper that turned Humanin from a curiosity into a research program.
Study 3 — The First Potent Analog In Vivo: Mamiya & Ukai, British Journal of Pharmacology, 2001
Citation: Mamiya T., Ukai M., “[Gly(14)]-Humanin improved the learning and memory impairment induced by scopolamine in vivo,” British Journal of Pharmacology 134:1597–1599.
What it did: Tested [Gly14]-Humanin — the S14G substitution now known as HNG — in live mice with scopolamine-induced memory impairment, and reported improvement. This was an early demonstration that a single amino-acid change (serine to glycine at position 14) produced a dramatically more potent molecule in a whole-animal behavioral model.
Why it matters: It launched the entire analog research program. The S14G change became the most-studied Humanin modification in the literature, and this paper is the reason later analog papers — HNGF6A, AGA-HNG, colivelin — all trace their lineage to position 14. Any top Humanin studies list that skipped it would be missing the field’s most productive branch.
Study 4 — The Bax Mechanism: Guo et al., Nature, 2003
Citation: Guo B. et al., “Humanin peptide suppresses apoptosis by interfering with Bax activation,” Nature 423(6938):456–461.
What it did: The Reed laboratory, which had independently discovered Humanin while screening for Bax-interacting proteins, showed that Humanin binds directly to Bax and blocks its activation — stopping the mitochondrial death cascade at one of its earliest steps. Follow-up work extended the binding to tBID and BimEL, other pro-death members of the Bcl-2 family, while showing Humanin ignores the family’s protective members.
Why it matters: This is the mechanism paper the whole field leans on. Before Guo et al., Humanin was a phenomenon in search of an explanation; after it, Humanin had a molecular address — the Bax-dependent apoptosis pathway. It is among the most-cited top Humanin studies and the standard citation for “how Humanin works inside the cell.”

Study 5 — The IGFBP-3 Connection: Ikonen et al., PNAS, 2003
Citation: Ikonen M. et al., Proceedings of the National Academy of Sciences 100:13042–13047 (2003) — the Cohen group’s paper reporting Humanin as an IGFBP-3 binding partner that antagonizes IGFBP-3’s pro-death actions.
What it did: Using a yeast two-hybrid screen, the Cohen laboratory — the third independent discoverer of Humanin — showed that Humanin binds insulin-like growth factor binding protein 3 (IGFBP-3) and antagonizes IGFBP-3’s pro-death actions on various cell types. Unexpectedly, the paper also reported that IGFBP-3 and Humanin cooperate to protect neurons from amyloid toxicity — a synergy that complicated the simple antagonist story.
Why it matters: This paper connected Humanin to the insulin/IGF signaling axis, which became the bridge to all of Humanin’s metabolic research — insulin sensitivity, diabetes models, and the 2009 finding that Humanin regulates peripheral insulin action. Without this study, the top Humanin studies would be a neuroscience list; with it, the list becomes a biology-wide list.
Study 6 — Proof It Exists In Vivo: Tajima et al., Neuroscience Letters, 2002
Citation: Tajima H. et al., “Evidence for in vivo production of Humanin peptide, a neuroprotective factor against Alzheimer’s disease-related insults,” Neuroscience Letters 324:227–231.
What it did: Addressed the skeptic’s question head-on: is Humanin actually produced in living tissue, or is it only a cell-culture phenomenon? The study provided evidence for endogenous in-vivo production of the peptide.
Why it matters: Endogenous existence is what separates a lab reagent from a physiological molecule. This paper let the field treat Humanin as a real circulating factor — which in turn justified the later observational studies measuring Humanin levels in human blood across aging and disease. A quiet paper, but a load-bearing one in the top Humanin studies canon.
Study 7 — The Analog Prevents Memory Impairment: Tajima et al., Journal of Neuroscience Research, 2005
Citation: Tajima H. et al., “A humanin derivative, S14G-HN, prevents amyloid-beta-induced memory impairment in mice,” Journal of Neuroscience Research 79:714–723.
What it did: Tested the S14G-HN (HNG) analog in mice with amyloid-beta-induced memory impairment and reported prevention of the deficit — moving the analog story from cell culture (2001) into an Alzheimer’s-relevant behavioral model.
Why it matters: It is the cleanest early demonstration that the engineered analog works in the disease model the field cares about most. Later analog papers cite this as the proof-of-concept that justified the whole HNG/HNGF6A/colivelin program.

Study 8 — The Metabolic Turn: Muzumdar et al., PLoS ONE, 2009
Citation: Muzumdar R.H. et al., “Humanin: A Novel Central Regulator of Peripheral Insulin Action,” PLoS ONE (PMC2709436).
What it did: Reported that Humanin acts in the brain to regulate insulin action in peripheral tissues — a central-to-peripheral metabolic axis. This reframed Humanin from a purely cytoprotective molecule into a metabolic regulator.
Why it matters: It opened the diabetes and metabolism wing of Humanin research, which is now one of the field’s largest branches. For readers of top Humanin studies lists who only know the Alzheimer’s story, this is the paper that shows the molecule’s second career.
Study 9 — The Field’s Map: Yen et al., Journal of Molecular Endocrinology, 2013
Citation: Yen K. et al., “The emerging role of the mitochondrial-derived peptide humanin in stress resistance,” Journal of Molecular Endocrinology 50(1):R11–R19 (PMC3705736).
What it did: Not an experiment but a synthesis: the Cohen group’s review organized a decade of scattered findings — discovery, Bax mechanism, IGFBP-3, receptors, metabolic effects — into a single framework of mitochondrial stress signaling.
Why it matters: Reviews do not discover, but they direct. This became the most-cited single overview of Humanin and the paper new researchers read first when working through the top Humanin studies. It also formalized the “mitochondrial-derived peptide” framing that now organizes the entire MDP field, including MOTS-c and the SHLPs (see our longevity peptides research overview).
Study 10 — Beyond the Brain: Zárate et al., Frontiers in Aging Neuroscience, 2019
Citation: Zárate S.C. et al., “Humanin, a Mitochondrial-Derived Peptide Released by Astrocytes, Prevents Synapse Loss in Hippocampal Neurons,” Frontiers in Aging Neuroscience 11:123.
What it did: Showed that astrocytes — the brain’s support cells — release Humanin, and that this astrocyte-derived Humanin prevents synapse loss in hippocampal neurons. It moved the story from “a peptide that protects cells” to “a peptide brain cells use to protect each other.”
Why it matters: It is representative of the modern phase of top Humanin studies: less about whether Humanin protects, more about how the body deploys it. The paracrine angle — cells signaling neighbors with Humanin — is where current research is heading.

How to read this list like a researcher
Notice the arc: a 2001 screen finds a phenomenon; 2001–2003 papers characterize it and find its mechanism; a 2002 paper proves it exists in living tissue; 2005–2009 papers extend it to analogs and metabolism; a 2013 review maps the territory; 2019 work shows how cells deploy it. That is how a research field matures — and it is the pattern to look for in any peptide literature, including the compounds in our selank vs semax research comparison.
Top Humanin Studies: Frequently Asked Questions
Short answers on the top Humanin studies above.
Which single Humanin paper should I read first?
The 2001 Hashimoto discovery paper (PubMed 11371646) for the origin, then the 2013 Yen review (PMC3705736) for the full landscape. Those two cover the top Humanin studies arc from founding experiment to mature field.
Which study established how Humanin works?
Guo et al., Nature 2003: direct binding to Bax, blocking its activation. Later work added tBID and BimEL binding plus the receptor pathways (gp130/WSX-1/CNTFR, JAK2/STAT3), but the Bax paper is the mechanistic anchor.
Are any of the top Humanin studies human clinical trials?
No. The top Humanin studies are preclinical — cell cultures, mouse and rat models — plus observational human biomarker data. There are no published human trials administering Humanin. Our registry-landscape guide covers what ClinicalTrials.gov actually contains.
Which study matters most for Humanin analogs?
Mamiya & Ukai 2001 ([Gly14]-Humanin in mice) for launching the S14G program, and Tajima et al. 2005 (S14G-HN preventing amyloid-induced memory impairment) for validating it in a disease model. Everything in the analog family descends from position 14.
Where does metabolism enter the Humanin story?
Through Ikonen et al. 2003 (the IGFBP-3 interaction) and decisively with Muzumdar et al. 2009 (PMC2709436), which reported Humanin as a central regulator of peripheral insulin action. That paper opened the diabetes-research wing of the field.
Is the Humanin literature still growing?
Yes. Recent years have added astrocyte-release studies, cardiovascular work, aging-biomarker studies, and a growing analog literature (HNGF6A, AGA-HNG, colivelin). The 2023 MDPI review “Neuroprotective Action of Humanin and Humanin Analogues” catalogs the modern analog table — the field is active, not settled.
Key Takeaways: Top Humanin Studies
- The top Humanin studies form a clear arc: 2001 discovery → 2001–2003 characterization and Bax mechanism → 2002 in-vivo proof → analog and metabolic expansion → 2013 synthesis → modern paracrine research.
- Three papers anchor everything: Hashimoto 2001 (discovery), Guo 2003 (Bax mechanism), Yen 2013 (field review).
- The S14G analog story — launched by Mamiya & Ukai 2001 — became the field’s most productive branch.
- All influential studies are preclinical or observational; none are human trials of Humanin administration.
- This summary is educational and research-framed only; Humanin remains a research compound, not an approved medicine.
Top Humanin Studies: Final Notes
The top Humanin studies tell a satisfying scientific story: an unbiased screen finds something unexpected, independent labs confirm it three different ways, a mechanism paper explains it, and two decades of follow-up turn one peptide into a field spanning neuroscience, metabolism, and aging biology. For anyone evaluating newer Humanin claims against the top Humanin studies, this list is the reality check — real influence leaves a paper trail, and this is the trail.
From here, the natural next reads are the registry record (what clinical databases actually list for Humanin) and the analog catalog (what chemists have built from the 2001 discovery). Both have their own guides in this series. And for the broader research-peptide landscape, our Semax nasal spray and Selank nasal spray research overviews — alongside our Semax 10mg and Selank 10mg research listings — apply the same study-first framing to other compounds.


1 Comment